FDA Approved: NEUPOGEN — Supplemental Application (Amgen, Inc)

View source ↗

Summary

The FDA approved a supplemental application for NEUPOGEN (filgrastim) from Amgen, formalizing changes to its indication/label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neutropenia

Drugs mentioned

• Neupogen (Filgrastim)

Snippet

SUPPL AP for NEUPOGEN (FILGRASTIM)